Financials.page
Company Fundamentals
Workspace
OverviewhomeCompaniesdirectoryLeague tablesrankingsAPI & MCPdevelopers
Company financial data, refreshed daily. Not investment advice.
Financials.page — company financial data, refreshed daily. Not investment advice. Legal & terms
Annual figures as reported in 10-K / 20-F / 40-F filings.
PPCB · CIK 0001517681

PROPANC BIOPHARMA, INC.

Annual figures as reported, FY2015–FY2026. Ratios and growth rates derived on-page.

PPCB logo
Pharmaceutical Preparations
Company profile
Nasdaq · PPCBHQ Camberwell, Victoria, AustraliaIncorporated in DEFiscal year ends Jun 30Non-accelerated filer Smaller reporting company
Net income
−$18.9M
▲ +68.0% vs FY2025
Free cash flow
−$5.7M
▼ −175.7% vs FY2019
Diluted EPS
−$17.62
▲ +95.3% vs FY2025

Net income

Losses shown in terracotta

−40M−20M0’15’17’19’21’23’25’26−$18.9M

Recent quarters

momentum · last 12 quarters
Net income — Jun ’26 quarter
−$4.6M
▼ −12.3% vs Jun ’25
Diluted EPS — trailing 12 months
−$17.62
▲ +95.3% vs Jun ’25

Quarterly net income

Losses shown in terracotta

−40M−20M0Sep ’23Mar ’24Sep ’24Mar ’25Sep ’25Mar ’26Jun ’26−$4.6M
QuarterRevenueRev. YoYGross marginNet incomeNet marginDiluted EPS
Jun ’26———−$4.6M—−$16.65
Mar ’26———−$6.4M—−$0.28
Dec ’25———−$3.1M—−$0.30
Sep ’25———−$4.8M—−$0.39
Jun ’25———−$4.1M—−$290.52
Mar ’25———−$54.1M—−$12.50
Dec ’24———−$430K—−$32.23
Sep ’24———−$354K—−$35.97

Profitability & returns

quality of earnings

Returns on capital

Net income vs year-end equity and assets

-15000%-10000%-5000%0%’15’17’19’21’23’25
Return on equityReturn on assets

Cash flow

cash generation

Free cash flow

Operating cash flow less capital expenditure

−4M−2M0’15’16’19’26−$5.7M

Operating cash flow

Net cash from operations

−4M−2M0’15’17’19’21’23’25’26−$5.7M

Shareholder returns

capital allocation

Diluted shares outstanding

Falling count means buybacks outpace dilution

01M2M3M’21’22’23’24’25’261M

Balance sheet

financial position

Stockholders’ equity

At fiscal year end

010M’15’17’19’21’23’25’26$9.4M

Growth rates

compounding, annualized

Cash flow & share count

FCF compounding; share count as total change

-60%-40%-20%0%Share count change (split-adjusted, total)5Y−62.9%

Key ratios

derived per fiscal year
Fiscal yearROEROACurrent ratioDebt / equity
FY2026−200.6%−147.6%2.55×—
FY2025−423.7%−300.1%1.50×0.04×
FY2024—−2515.8%0.01×—
FY2023—−4410.2%0.01×—
FY2022—−3255.4%0.00×—
FY2021—−15464.1%0.00×—
FY2020—−4812.0%0.02×—
FY2019—−5664.8%0.02×—
FY2018—−9860.6%0.01×—
FY2017—−8275.6%0.01×—
FY2016—−2482.0%0.12×—
FY2015—−544.2%0.17×—

Annual figures

as reported
Fiscal yearRevenueGross profitOp. incomeNet incomeDiluted EPSOp. cash flowCapexTotal assetsLiabilitiesEquityCashLT debt
FY2026——−$18.2M−$18.9M−$17.62−$5.7M$5K$12.8M$3.4M$9.4M——
FY2025——−$57.3M−$58.9M−$371.22−$405K—$19.6M$5.7M$13.9M—$538K
FY2024——−$1.5M−$1.8M−$1420.53−$935K—$72K$3.9M−$3.8M—$399K
FY2023——−$1.8M−$2.7M−$1.80−$1.1M—$60K$3.2M−$3.1M—$391K
FY2022——−$2.0M−$2.7M−$49.23−$1.4M—$82K$3.1M−$3.0M—$926K
FY2021——−$1.8M−$2.0M−$0.80−$1.1M—$13K$3.1M−$3.1M—$625K
FY2020——−$3.5M−$4.7M−$192.45−$1.8M—$99K$3.7M−$3.6M—$1.6M
FY2019——−$2.6M−$5.8M−$10.97−$2.1M$3K$102K$4.4M−$4.3M—$1.7M
FY2018——−$4.0M−$7.0M−$178.75−$2.2M—$71K$6.8M−$6.8M—$4.7M
FY2017——−$5.7M−$7.9M−$2.24−$2.1M—$95K$5.5M−$5.4M—$3.5M
FY2016——−$6.9M−$9.4M−$4.83−$4.5M$10K$379K$2.9M−$2.6M—$1.2M
FY2015——−$1.7M−$3.4M−$0.02−$1.4M$4K$627K$3.7M−$3.1M——

Latest filings

the most recent regulatory filings
10-KAnnual report2026-09-25 ↗DEF 14CSEC filing2026-08-21 ↗PRE 14CSEC filing2026-08-05 ↗EFFECTSEC filing2026-07-27 ↗S-1Securities registration2026-07-17 ↗8-KCurrent report — material event2026-07-14 ↗10-QQuarterly report2026-05-14 ↗EFFECTSEC filing2026-04-20 ↗CORRESPSEC filing2026-04-16 ↗UPLOADSEC filing2026-04-15 ↗

Company logos by Elbstream and unavatar.

All third-party trademarks, service marks, logos, and brand names used on this site are the property of their respective owners. The use of these logos is for identification and illustrative purposes only and does not imply any affiliation, sponsorship, or endorsement by the respective owners.